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Abstract
Background: Microarray experiments produce expression measurements in genomic scale. A way to derive functional
understanding of the data is to focus on functional sets of genes, such as pathways, instead of individual genes. While a
common practice for the pathway-level analysis has been functional enrichment analysis such as over-representation
analysis and gene set enrichment analysis, an alternative approach has also been explored. In this approach, gene
expression data are first aggregated at pathway level to transform the original data into a compact representation in
which each row corresponds to a pathway instead of a gene. Thereafter the pathway expression data can be used for
differential expression and classification analyses in pathway space, leveraging existing algorithms usually applied to
gene expression data. While several studies have proposed the pathway-level aggregation methods, it remains unclear
how they compare with one another, since the evaluations were done to a limited extent. Thus this study presents a
comprehensive evaluation of six most prominent aggregation methods.
Results: The compared methods include five existing methods–mean of all member genes (Mean all), mean of
condition-responsive genes (Mean CORGs), analysis of sample set enrichment scores (ASSESS), principal component
analysis (PCA), and partial least squares (PLS)–and a variant of an existing method (Mean top 50%, averaging top
half of member genes). Comprehensive and stringent benchmarking was performed by collecting seven pairs of
related but independent datasets encompassing various phenotypes. Aggregation was done in the space of KEGG
pathways. Performance of the methods was assessed by classification accuracy validated both internally and
externally, and by examining the correlative extent of pathway signatures between the dataset pairs. The
assessment revealed that (i) the best accuracy and correlation were obtained from ASSESS and Mean top 50%,
(ii) Mean all showed the lowest accuracy, and (iii) Mean CORGs and PLS gave rise to the largest extent of
discordance in the pathway signature correlation.
Conclusions: The two best performing method (ASSESS and Mean top 50%) are suggested to be preferred. The
benchmarking analysis also suggests that there is both room and necessity for developing a novel method for
pathway-level aggregation.
Background
Microarray gene expression experiments produce high
dimensional expression measurements in genomic scale,
typically expression levels of more than ten thousand
genes. While the high dimensionality offers an opportunity
for a comprehensive interrogation of transcriptome, it also
poses a challenge to researchers seeking to extract func-
tional understanding and interpretation of the data, which
go beyond a mere identification of differentially expressed
genes (DEGs). A way to derive such a functional interpre-
tation is to focus on functional sets of genes, such as biolo-
gical pathways, instead of individual genes. A common
practice for the pathway-level analysis has been the func-
tional enrichment analysis, for which two types of meth-
ods are widely used. One is called over-representation
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analysis in which DEGs are first identified from the data
and their prevalent pathway annotations are then identi-
fied, whose best known example is DAVID [1]. The other
is called gene set analysis in which differential expression
statistics of all genes are first computed and each pathway
is then examined to see whether its member genes collec-
tively show significant differential expression, whose best
known example is Gene Set Enrichment Analysis (GSEA)
[2]. A common theme underlying the two types of func-
tional enrichment analysis is that individual genes are first
tested for differential expression and the resultant gene-
level results are then combined at the pathway level for an
identification of differentially regulated pathways.
An alternative approach is also possible, where gene
expression data are first aggregated at pathway level to
yield a compact representation of the original data, in
which each row in the data matrix now corresponds to a
pathway instead of a gene. Thereafter the pathway-level
aggregated expression data, or simply, pathway expression
data, are directly analyzed to identify differentially
expressed pathways. A notable advantage of the aggrega-
tion-based approach is that it can be applied to a wider
range of analysis tasks than the conventional functional
enrichment analysis. This is because, once gene expression
data are aggregated at pathway level, the pathway expres-
sion data can not only be used for identifying differentially
expressed pathways, but also for classification or clustering
of samples in the space of pathways [3,4], leveraging exist-
ing algorithms usually applied to gene expression data.
Transforming the expression data from gene space to
pathway space is also expected to yield a more robust
representation of the data in which intrinsic technological
and biological variances across samples are reduced [5]. In
other words, while expression of individual genes in a
pathway may vary considerably across samples with simi-
lar phenotypic characteristics, expression of the pathway
as a whole may become consistent across the samples.
Noting the advantages in interpretability, compactness,
utility, and anticipated robustness, several studies have
proposed pathway-level aggregation methods of gene
expression data [3,5-10].
With the availability of all these pathway-level aggrega-
tion methods, it becomes important to comprehensively
evaluate how these methods compare with one another.
Although each of the original reports has presented an
evaluation of its performance for a demonstration of its
improvements over existing methods, the evaluations were
done only to a limited extent and thus inadequate to make
general recommendations. Most notably, there were the
following two major limitations.
The first limitation is that, in the studies in which classi-
fication accuracy was assessed in the pathway space
[3,5,8,9], external validation of accuracy on related but
independent test datasets was either skipped (employing
internal cross-validation only) [5], or insufficiently done
on a limited number of datasets (only two pairs of training
and test datasets) [3,8,9]. Although internal cross-valida-
tion is a convenient solution to assess a classifier’s perfor-
mance within a single dataset, it leads to optimistically
higher estimates of performance than what would really
be expected in a new dataset with identical phenotypic
classes [11,12]. Thus, in any classification studies, it is
increasingly being recognized that it is crucial to externally
validate the performance of a classifier constructed from a
dataset on an independent test dataset for a realistic esti-
mation of classification performance and generalizability
[11,12]. In addition, to ensure a comprehensive evaluation,
the training and the external validation need to be per-
formed on multiple pairs of training and test datasets that
encompass a wide range of phenotypes with varying extent
of relative subtlety in the biological differences between
phenotypic classes.
The second limitation is that all the original reports did
not evaluate the extent to which the differential expression
signature of pathways is correlated between datasets with
identical phenotypic classes. As described earlier, an
expectation with the pathway-level aggregation has been
that, although differential expression signature of genes
may show some discrepancy between related datasets, dif-
ferential expression signature of pathways may become
more congruent with each other. Despite the importance
as an evaluation metric, the correlative extent of pathway
signature has not been evaluated in the original reports.
To address the aforementioned limitations towards a
reliable assessment, this study presents a comprehensive
evaluation of six most prominent pathway-level aggrega-
tion methods of gene expression data–five existing meth-
ods and a simple variant of an existing method. Datasets
collected for benchmarking consist of seven pairs of two-
class gene expression datasets (fourteen datasets in total)
of various phenotypes. The gene expression datasets were
aggregated in the space of KEGG pathways. The perfor-
mance of the pathway-level aggregation methods was
assessed by classification accuracy validated both internally
and externally, and by correlation of pathway signatures.
Results
Description of six compared methods of pathway-level
aggregation
This study compared six of the most prominent methods
for pathway-level aggregation of gene expression data. For
an illustrative purpose, an example of a gene expression
profile and corresponding pathway expression profiles
aggregated by the six methods is provided as heatmaps in
Figure 1. The six methods can be grouped into three gen-
eral categories: mean-based (mean of all genes, mean of
condition-responsive genes, and mean of top 50% of
genes), projection-based (principal component analysis
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(A) Gene expression profile
(B) Pathway expression profile aggregated by six methods
Never smokers Current smokers
Figure 1 Illustration of pathway-level aggregation of gene expression data. (A) A gene expression data in which the effect of smoking on
bronchial epithelium was investigated by comparing current smokers and never smokers (the Beane dataset in Table 1). To save space,
expression levels of 76 selected genes are shown, which are the member genes of two major pathways mediating the effect of smoking. (B)
Corresponding pathway expression profiles aggregated by the six compared methods. With this compact representation of the original gene-
level data, it becomes easier to recognize that the two pathways are up-regulated by smoking.
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and partial least squares), and others (analysis of sample
set enrichment scores). Description of each of the methods
is given below. Mathematical description of the methods is
provided in Additional file 1.
Mean of all genes (Mean all)
In this most straightforward method, which has appeared
in the literature many times in one form or the other
[4,9,10,13,14], the gene expression data are first z-scaled
for each gene across the samples into zero mean and unit
variance. Then the expression profiles of all member genes
in a pathway are combined by taking their mean.
Mean of condition-responsive genes (Mean CORGs)
In this method [8], expression profile of a pathway is
represented by the mean expression of key member
genes, called CORGs (condition-responsive genes),
instead of all the member genes. The CORGs are defined
as the genes that, upon aggregating their expression pro-
files by averaging, yield a pathway expression profile that
is the most discriminative between the two classes in the
data. Identifying the CORGs of a pathway in a given two-
class dataset begins with t-test on z-scaled expression
data of genes belonging to the given pathway. Then,
overall direction of expression change (that is, up or
down) in the pathway is determined as the sign of the
mean t-statistic values of all its member genes. Next, all
the member genes are sorted by their t-statistic values in
accordance with the overall regulatory direction of the
pathway; the most strongly up-regulated genes are
arranged to the top for an overall up-regulated pathway,
whereas the most strongly down-regulated genes are
arranged to the top for an overall down-regulated path-
way. Then, the CORG set is initially set to contain only
the top ranked gene, and iteratively expanded. At each
iteration, the gene of the next rank is added to the candi-
date CORG set, pathway expression profile is obtained
next by taking the mean of expression profiles of the can-
didate CORGs, and t-test is then performed to give the
pathway’s t-statistic. The iteration stops when the path-
way’s t-statistic no longer improves, at which point the
final CORG set is obtained. Although this method has
been called as PAC (Pathway Activity inference using
Condition-responsive genes) in the original article, it will
be referred to as Mean CORGs in this report in order to
emphasize the mean-based nature of the method as well
as to avoid confusion with PCA (principal component
analysis) which is one of the methods evaluated in this
article.
Analysis of sample set enrichment cores (ASSESS)
The ASSESS method [3] can be considered as a sample-
level extension of Gene Set Enrichment Analysis (GSEA)
[2]. As in the GSEA method, ASSESS calculates enrich-
ment score of each pathway. The difference is that, while
GSEA gives only an overall enrichment score of a pathway
between two classes of samples, ASSESS provides an
enrichment score of the pathway for each sample. To this
end, ASSESS employs random walk computations twice.
The first use of random walk is applied at the level of indi-
vidual genes. Given an expression level of a gene in a sam-
ple, the sample’s log likelihood ratio of belonging to one
class instead of the other is calculated. To calculate the log
likelihood ratio, it is needed to first calculate two probabil-
ities that the expression level of a gene in a sample is
representative of class 1 or class 2. Random walk is used
for this probability calculation. More detailed description
of the first use of random walk can be found in the origi-
nal publication [3]. Then the second use of random walk
is done at the level of each pathway. Using the log likeli-
hood ratio values obtained for its member genes, it com-
putes enrichment score of a pathway in a sample by the
maximum deviation of the random walk from zero, as in
GSEA.
Principal component analysis (PCA)
PCA has long been applied to the analysis of gene expres-
sion data, especially for an exploratory data visualization
to discriminate between sample groups. In this usage of
PCA, correlation matrix is first computed from z-scaled
gene expression data. Each element in the correlation
matrix represents a measure of dependencies between cor-
responding gene pairs, with zero indicates independence.
Then, through eigen-decomposition of the correlation
matrix, major directions in the data with the largest varia-
bility are identified as eigenvectors corresponding to the
largest eigenvalues of the correlation matrix. Or, equiva-
lently, the eigenvectors and eigenvalues of the correlation
matrix can also be found by singular value decomposition
(SVD) of the gene expression matrix itself. The eigenvec-
tors are called the principal components (PCs), or meta-
genes in gene expression studies. Finally, the gene
expression data are projected onto a small number of PCs,
usually two or three, and the projections are used for an
exploratory visualization of the data. The matrix of PCs is
commonly referred to as loadings, in which each column
gives the location of each PC axis relative to the original
system of axes. The matrix of projections is also com-
monly referred to as scores, in which each column gives
the location of samples with respect to each PC axis.
In addition to its use in the exploratory data visualiza-
tion, PCA has also been used as a pathway-level aggrega-
tion method in several studies [6,7,15]. In this usage, PCs
are found by applying PCA to the matrix of z-scaled
expression levels of member genes in a given pathway,
instead of all genes represented in the microarray. Projec-
tion of the gene expression data of the pathway onto the
first PC is taken as the expression profile of that pathway.
In this application of PCA as a pathway-level aggregation
method, it is worth mentioning that there exists an issue
called sign ambiguity [16], which is an inherent but often
overlooked aspect of PCA despite its wide usage in
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bioinformatics. The sign ambiguity refers to an intrinsic
property of PCA and SVD in which the orientations of
PCs, or equivalently, those of singular vectors, cannot be
mathematically determined. To see why, consider the
decomposition of a data matrix X, X = UΣVT, in which Σ
is a diagonal matrix and the columns of U and V are the
left and right singular vectors, respectively. In this decom-
position, the orientation of any right singular vector can
be flipped as long as the orientation of the corresponding
left singular vector is flipped as well. In other words, the
following equality holds for any column index k;
σkukvTk = σk (−uk) (−vk)T . Although any implementation
of PCA and SVD assigns singular vectors with specific
signs, the assignment of sign is essentially random [16].
What this entails in the context of pathway-level aggrega-
tion is that, for a pathway expression profile obtained
from PCA, positive and negative expression values may
not necessarily mean an up-regulation and a down-regula-
tion of the pathway, respectively. Thus, the sign of PC
scores lacks meaningful biological interpretation. While
the sign ambiguity problem has not been recognized in
some studies that used PCA as a pathway-level aggrega-
tion method [6,7], it was considered in other related stu-
dies [15,17] by correcting the signs of PC scores so that
the PC scores are positively correlated with the average
gene expression profile of the given module. This simple
approach for sign correction was adopted for the analysis
shown in this report.
Partial least squares (PLS)
PLS is a regression method that combines properties of
multiple regression and PCA. Data for PLS analysis con-
sist of a data matrix X and a response matrix Y, which
contain values of the independent and the dependent
variables, respectively. In brief, PLS seeks to find latent
variables (as opposed to observed variables) that best
summarize the variance in the original data X and are
the most relevant for the response Y as well. Unlike the
standard multiple regression which builds a regression
model between the original data X and Y, PLS seeks to
build a regression model between the latent component
scores of X and those of Y. Unlike PCA which chooses
the PCs so that only the variability within X is best
described, PLS chooses the latent components so that
covariance between X and the response Y is best
described. A previous study [6] has used PLS as a path-
way-level aggregation method. In this approach, data
consist of a matrix X of z-scaled expression levels of a
given pathway’s member genes and a class vector Y.
Each element in the class vector simply indicates class
membership of the corresponding sample. Score vector
of the first latent component is taken as the expression
profile of that pathway. As in the case of PCA, the sign
of the latent components needs to receive further
consideration. In the previous study [6], a dummy cod-
ing scheme was used to represent the class vector, 0 for
a control sample and 1 for a case sample. However, the
sign of the latent components obtained under this cod-
ing scheme lacks meaningful biological interpretation.
Since 1 is a larger numeric value than 0, regression on
these two dummy numeric values makes the resultant
pathway expression levels larger in case samples and
smaller in control samples. Thus subsequent differential
expression analysis at pathway level would falsely iden-
tify all pathways as being up-regulated. Thus, for the
analysis shown in this report, the sign of the latent com-
ponent scores was corrected so that the scores are posi-
tively correlated with average gene expression profile of
the given pathway–the same correction scheme used for
PCA. This correction scheme is also equivalent to the
use of 0/1 coding for an overall up-regulated pathway
and 1/0 coding for an overall down-regulated pathway.
Mean of top 50% of genes (Mean top 50%)
In addition to the five existing methods described above,
a simple variant of the first method (mean of all genes)
was proposed in this report. In this modification, path-
way expression profile is calculated by averaging only
the top half of the member genes with larger t-statistics,
instead of all member genes.
Collection of benchmarking datasets
For a comprehensive evaluation, a total of seven pairs of
independent datasets of various phenotypes was col-
lected, fourteen in total (Table 1). Each dataset will be
referred to by the name of the first author in the corre-
sponding article, or by the name of cohort. In all the
datasets, class 2 represents a more malignant sample
group than class 1. Thus class 2 was designated as the
case group and class 1 as the control group.
Internal cross-validation accuracies in each dataset
The ability of pathway expression profile for discrimi-
nating two sample groups was first assessed by 5-fold
cross-validation within each dataset (Figure 2). Balanced
accuracy was examined as a function of feature set size
(from top one to ten pathways, ranked by t-test on path-
way-level aggregated data), instead of at a fixed arbitrary
number of features, or an optimized number of features
that results in the best performance in the validation
dataset [8]. The adopted examination scheme allows a
transparent benchmarking of the compared methods
over an unbiased operative range, and is an often
adopted scheme in similar benchmarking analyses [8,31].
Several observations can be made from Figure 2. First, the
classification accuracy varied across datasets, which reflects
the relative subtlety in the biological differences between
two classes in each dataset. The highest (around 70%-
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100%) accuracies were obtained in the comparison of
tumorous kidney and normal kidney (Figure 2D), which are
markedly distinctive disease states. Somewhat lower accura-
cies were obtained in the remaining datasets. The lowest
accuracies (around 55%-80%) were obtained in the Sun
dataset (Figure 2C, right) which compared glioblastoma
multiforme (GBM) and anaplastic astrocytoma (AA)–the
two subtypes of high grade gliomas and also known as
grade IV and III astrocytoma, respectively. Second, there
were noticeable fluctuations in accuracies along the feature
set sizes, and their extent appeared to vary across datasets.
For example, the smoking dataset of Vanni showed the lar-
gest fluctuations (Figure 2G) whereas the kidney dataset
showed the smallest fluctuations (Figure 2D). With respect
to aggregation methods, it appears that there are more pro-
nounced fluctuations in some of the methods (Mean
CORGs, PCA, and PLS) than in the rest (Mean all, Mean
top 50%, and ASSESS). Third, some of the methods can be
recognized to yield lower accuracies than the others. For
example, PCA never achieved the highest accuracies across
all datasets and feature set sizes.
External validation accuracies in each pair of datasets
Having examined the classification accuracies by cross-
validation on the same datasets from which the classifiers
were derived, the accuracies were then re-assessed by
externally validating on independent datasets with identi-
cal phenotypic class labels. As in the internal validation,
there were noticeable fluctuations in accuracies along the
feature set sizes, and their extent appeared to vary across
datasets. For example, the smoking datasets showed the
largest fluctuations (Figure 3G), the kidney datasets
showed the smallest fluctuations (Figure 3D), and the
lung cancer subtype datasets showed medium fluctua-
tions (Figure 3F). As in the internal validation, it appears
that there are more pronounced fluctuations in some of
Table 1 Seven pairs (fourteen in total) of independent microarray datasets used for benchmarking
Phenotype Dataset name and
reference
Class 1 (control group)
samples





Effect of smoking on bronchial epithelium Never smokers Current smokers
Beane [18] 21 52 GSE7895 U133A
Vanni [19] 22 37 GSE10135 U133
Plus 2
Subtypes of non-small cell lung cancer
(NSCLC)
AD (adenocarcinoma) SCC (squamous cell
carcinoma)
Bild [20] 58 53 GSE3141 U133
Plus 2
Lee [21] 63 75 GSE8894 U133
Plus 2




Phillips [22] 21 56 GSE4271 U133 Set
Sun [23] 19 77 GSE4290 U133
Plus 2
Estrogen receptor (ER) status in breast
cancer
ER-negative ER-positive
Chin [24] 46 84 E-TABM-158 U133A
Minn [25] 42 57 GSE2603 U133A
Breast cancer grade Grade 1 Grade 3
Desmedt [26] 30 83 GSE7390 U133A
Sotiriou [27] 28 32 GSE2990 U133A
Lung cancer grade Grade 1 Grade 3
Dana-Farber [28] 13 37 Author’s
website
U133A
Michigan [28] 26 66
Clear cell renal cell carcinoma (CCRCC) vs
Normal kidney
Normal kidney Tumorous kidney
Jones [29] 23 32 GSE15641 U133A
Kort [30] 12 10 GSE11024 U133
Plus 2
Each of the datasets was referred to in the main text by the dataset name, which is the first author’s name or cohort name. Numbers in the table indicate the
number of samples.
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the methods (Mean CORGs, PCA, and PLS) than in the
rest (Mean all, Mean top 50%, and ASSESS). Apart from
the aforementioned qualitative observations, the presence
of the dataset-dependent and feature set size-dependent
fluctuations in accuracies makes it difficult to further
compare quantitatively the relative performance of the
six methods. For example, while it should be relatively
straightforward to compare the methods in the breast
cancer ER subtype dataset which showed relatively small
























































































































(B) Breast cancer — Grade 3 vs Grade 1
(C) Glioma — GBM vs AA (D) Kidney — Tumor vs Normal
(E) Lung cancer — Grade 3 vs Grade 1 (F) Lung cancer — SCC vs AD
(G) Smoking — Current vs Never






Figure 2 Internal cross-validation balanced accuracy in the fourteen datasets. Balanced accuracy is plotted as a function of the number of
top pathways added to the classifier, ordered by t-test on pathway-level expression data aggregated by the six compared methods.
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the smoking dataset which showed a high extent of fluc-
tuation (Figure 3G). To facilitate further comparison, a
summarized view of accuracies across all the datasets was
thus obtained using a rank-based method, as described in
the next section.
Overall accuracy ranking combined across the datasets
To simplify the comparison of the methods, it would
be helpful to summarize the accuracy results by con-
verting them into a ranking of the six methods in each
























































































































(B) Breast cancer — Grade 3 vs Grade 1
(C) Glioma — GBM vs AA (D) Kidney — Tumor vs Normal
(E) Lung cancer — Grade 3 vs Grade 1 (F) Lung cancer — SCC vs AD
(G) Smoking — Current vs Never






Figure 3 External validation balanced accuracy in the seven pairs of datasets. The general format of the plots is the same as in Figure 2.
The arrow (- >) in the plot title designates the training and test datasets. For example, “Chin - > Minn” denotes that the classifier was trained on
the Chin dataset and tested on the Minn dataset.
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fourteen datasets. To this end, we used RankAggreg
package [32] which produces a combined ranked list
when given with several ranked lists. The rank combi-
nation was done for the external validation results as
well as for the internal validation results. The com-
bined ranking of the six methods at each feature set
size is shown in Figure 4.
With such ranking-based summarized representation,
relative performance of the six methods becomes more
evident. In the internal validation (Figure 4A), Mean top
50% achieved the highest accuracy ranks across all fea-
ture set sizes, whereas PCA achieved the lowest accu-
racy ranks. Overall, the combined accuracy ranking
showed only a small extent of fluctuation in the internal
validation, despite the fluctuations in accuracy values
within individual datasets. In the external validation
(Figure 4B), there were considerable fluctuations in the
combined accuracy ranking. Nevertheless, relative per-
formance of the six methods was distinguishable despite
the fluctuations. By comparing Figure 4B with Figure
4A, it can be observed that the external and the internal
validation results are generally similar. First, on average,
Mean top 50% achieved the highest accuracy rank in
both the external validation (average rank of 1.7) and
the internal validation (average rank of 1.0). Second,
PCA ranked the second lowest in the external validation
(average rank of 4.9) and the lowest in the internal vali-
dation (average rank of 5.8). Third, Mean CORGs
achieved a medium accuracy rank in both validations.
Fourth, ASSESS achieved the second highest accuracy
rank in both validations. On the other hands, disparate
observations can also be made between the external and
the internal validation results. For example, although
PLS ranked consistently near the bottom in the internal
validation, it showed a steady decrease in accuracy rank
in the external validation as more pathways are added
to the classifiers, yielding a medium average rank of 3.3.
While the results from the internal and external valida-
tion showed both similarities as well as discrepancies,
the results from the external validation should receive
more weight since the external validation is a more rea-
listic way to estimate the true performance and general-
izability of a classifier, as argued in the Introduction
section. Therefore, in subsequent sections, further exam-
inations of the classification performance were made to
the externally validated results only.
Overall distribution of accuracies pooled across the
datasets and feature set sizes
To further summarize the external validation results
shown in Figure 3, overall distribution of accuracies was
obtained for each of the six methods by pooling their
accuracies obtained under all the fourteen datasets and
ten feature set sizes, and represented as boxplots (Figure
5). With respect to median accuracy, three methods
(Mean top 50%, ASSESS, and PLS) similarly showed a
higher accuracy (around 80%), whereas Mean all and
PCA showed a lower accuracy (around 70%). With
respect to dispersion, four methods (Mean all, Mean top
50%, ASSESS, and PCA) showed a similar extent of dis-
persion, whereas Mean CORGs and PLS showed a high
extent of dispersion, with a small lower quartile value
(around 50%). Considering both the median accuracy
and the dispersion, Mean top 50% and ASSESS thus
showed a similarly good performance across all the data-
sets and feature set sizes. Although PLS showed a good
median accuracy, its accuracies varied the most across
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Figure 4 Overall accuracy ranking of the methods combined across the datasets. Combined accuracy ranking of each method is plotted
as a function of the number of top pathways. The numbers in the right of the plots are the average rank across the ten feature set sizes. (A)
Internal cross-validation. (B) External validation.
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Overall distribution of accuracies in each phenotype
The external validation results shown in Figure 3 were also
summarized for each of the six methods by pooling their
accuracies at all feature sizes and two independent data-
sets in each phenotype (Figure 6). A main observation is
that the relative performance of the methods varies across
phenotypes. While the median accuracies of all the meth-
ods are relatively similar in some phenotypes (Figures 6B,
D, and 6F), there are large differences in other phenotypes
(Figures 6E and 6G). What this observation entails is that
the performance evaluation should be performed in as
many phenotypes as possible, as done in this study.
Between-dataset correlation of differential expression
statistics of pathways
Comparison of the methods can also be performed by
evaluating the extent to which the differential expression
statistics of pathways are correlated between independent
datasets. To this end, Student’s t-test was performed on
pathway expression profiles to obtain t-statistics of each
pathway in each of the datasets. In total, seven pairs of
pathway signatures were obtained per method. Thus, for
a given phenotype, one can correlate a pathway’s t-statis-
tic in one dataset with its t-statistic in the other dataset.
To obtain a summarized view, a scatterplot of t-statistics
was prepared for each method by correlating t-statistic
values of all the pathways between seven pairs of datasets
(Figure 7). Thus each plot contains 1,141 data points
(163 pathways times 7 phenotypes). Two main observa-
tions can be made from the scatterplots. First, lower
correlations were observed under three methods (Mean
CORGs, PCA, and PLS) than the rest (Mean all, Mean
top 50%, and ASSESS). Second, the three methods with
lower correlations have many discordant pathways whose
t-statistics are large in magnitude and in the opposite
sign between the two independent datasets (quadrants II
and IV). It is these discordant pathways that, when used
as a feature, dropped the external validation accuracy and
caused the observed fluctuation of accuracies shown in
Figure 3.
To further examine the discordant pathways, an exem-
plar pathway was selected among the top 10 feature
pathways used in the classification analysis. Since the
lung cancer grade datasets showed lower accuracies
(Figure 6E) under the three methods (Mean CORGs,
PCA, and PLS) than the rest, an exemplar pathway was
selected from the feature pathways in the lung cancer
grade datasets. One of the most discordant pathways
with the largest magnitude of t-statistic values was
MAPK signalling pathway, whose 244 member genes are
represented in the microarray data. In Mean CORGs, it
was the most up-regulated pathway in one dataset
(Dana-Farber) but fifth most down-regulated pathway in
the other (Michigan) (data not shown). In PLS, it was
also the most up-regulated pathway in the Dana-Farber
dataset but ranked the twenty-first as a down-regulated
pathway in the Michigan dataset (data not shown). Its
t-statistics in the lung cancer grade datasets are indi-
cated as large red circles in Figure 7, and its member
genes’ expression profile along with its pathway expres-
sion profiles aggregated by the six methods are shown in
Figure 8. Three observations can be made from Figure 8.
First, differential expression between the grade groups
becomes more evident with pathway expression profiles
(Figure 8B) than gene expression profile (Figure 8A).
Second, the direction of pathway-level expression change
is discordant between the two cohort datasets. In the
grade 3 samples, the MAPK signalling pathway is up-
regulated in the Dana-Farber cohort (Figure 8B, left) but
down-regulated in the Michigan cohort (Figure 8B,
right). Third, the extent of differential expression of the
pathway is more pronounced under Mean CORGs and
PLS, as all the samples within each grade group show
relatively homogeneous expression levels.
Discussion
This study evaluated and compared the six methods of
pathway-level aggregation of gene expression data–five
existing methods (Mean all, Mean CORGs, ASSESS, PCA,
and PLS) and a simple variant of an existing method
(Mean top 50%). Four of the compared methods are either
conventional dimensionality reduction methods (PCA and
PLS) or simple heuristics (Mean all and Mean top 50%).

























Figure 5 Overall distribution of accuracies across all the
datasets and all feature set sizes. The distribution was obtained
from the external validation results. Median accuracies are joined by
grey line.
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address the pathway-level aggregation problem itself. It
may be argued that the former lacks a solid biological
basis and the latter a formal basis. The other two methods
(Mean CORGs and ASSESS) were specific to the pathway-
level aggregation problem. The evaluation was performed
with respect to classification accuracy, validated both
internally and externally, and by examining the correlative
extent of pathway signatures between seven pairs of
related but independent datasets. The results show that
there are considerable differences in performance between
the methods. Three main findings from this study are
described below. First, with respect to the external valida-
tion accuracy, the six methods can be ranked from
the best to the worst as Mean top 50%, ASSESS, PLS,
Mean CORGs, PCA, and Mean all (Figure 4B). The
dimensionality reduction methods were overall inferior to
others. Second, the overall distribution of accuracies is
skewed down inMean CORGs and PLS (Figure 5), indicat-
ing that there are many instances in which these two
methods did not perform well. Third, the reason why
these two methods perform poorly in such instances is that
they tend to produce pathway expression signatures that
are discordant between related but independent datasets,
as shown in the pathway t-statistic correlation (Figure 7).
The between-dataset discordance arises due to the algo-
rithmic characteristics of the two methods. In Mean
CORGs, the pathway’s overall direction of expression
change is first determined as the sign of mean t-statistic
values of all its member genes. Then, only the key member



























(A) Breast Cancer - ER+ vs ER-
(D) Kidney - Tumor vs Normal
(G) Smoking - Current vs Never
(B) Breast cancer - Grade 3 vs Grade
(E) Lung cancer - Grade 3 vs Grade 1
(C) Glioma - GBM vs AA








Figure 6 Overall distribution of accuracies across all feature set sizes in each phenotype. The format of the plots is the same as in Figure
5. Unlike Figure 5, accuracies were pooled only across the ten feature set sizes and two independent datasets that belong to a phenotype.
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t-statistic are selected. Thus, if the pathway’s overall
expression change is in different directions between data-
sets even by a small magnitude, the discordance in the
resultant pathway expression profiles becomes inflated.
Similarly, in PLS, the sign of the latent components was
corrected so that the component scores are positively cor-
related with the average gene expression profile of the
given pathway. Thus, the pathway expression profile aggre-
gated by PLS becomes discordant in the opposite direction
as well.
The third observation described above suggests that, in
order to yield a pathway expression profile that is concor-
dant between independent datasets and predictive of a phe-
notype as well, a successful pathway-level aggregation
method should not strictly depend on the overall direction
of expression change of a pathway, as measured by the
mean of z-scaled expression levels of its member genes.
Although it is the simplest and the most widely used prac-
tice that regards a pathway being up-regulated if the mean
expression is positive and down-regulated if negative, such
a rationale lacks solid biological support. It has been argued
that, in physiological processes such as biological pathways,
homeostatic transcriptional responses may occur so that
an up-regulation of one component in a pathway leads to a
down-regulation of another component in that pathway in
an attempt to compensate [33]. If so, overall direction of a
pathway’s expression change is determined by the relative
magnitudes of the two opposing components. If, for some
reason, the relative magnitudes of the two components are
reversed between independent datasets, the overall direc-
tion of a pathway’s expression change would become dis-
cordant in the opposite direction. Furthermore, simply
averaging the expression changes of all the member genes
as if they were independent and uniform objects may not
lead to an adequate measure for representing a pathway’s
expression behavior in a biological context, considering
that differential expression of downstream genes in a path-
way may not influence the pathway’s overall activity as
much as that of its upstream genes [34]. Thus, I speculate
that a successful pathway-level aggregation method needs
to consider the issues such as the homeostatic response of
a pathway, the positions of genes in the pathway topology,
as well as the types of interaction linking the member
genes. The last two issues have also been mentioned in a
review paper describing topology-based pathway enrich-
ment analysis methods [35].
Between-dataset correlation of pathway t-statistics































































Figure 7 Between-dataset correlation of pathway t-statistics. In each scatterplot, Pearson correlation coefficient and linear regression line are
shown. Quadrants are indicated as Roman numerals. Pathways in the quadrants II and IV are the discordant pathways. A large red circle denotes
an exemplar pathway (MAPK signalling pathway) which is further discussed in the main text. For ASSESS, four outlier data points (with absolute
t-statistics of 40 - 70) were removed to keep all six plots under a comparable scale.
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The pathway-level aggregation approach is advanta-
geous in that it can be used not only for identifying dif-
ferentially expressed pathways, but also for classification
or clustering samples in the space of pathways, for
deriving a compact representation and visualization of
the original gene expression data, as well as for facilitat-
ing systems-level interpretation. Nevertheless, an inher-
ent problem of the pathway-level aggregation approach
is a possible loss or even deformation of information
present in the original gene expression data. This pro-
blem arises since the expression levels of pathway mem-
ber genes are reduced into a single numerical value. In
this regard, a relationship may exist between the discri-
minative ability of a pathway expression profile and the
size of the pathway, since the size of a pathway may
indicate either complexity or extent of characterization
of the pathway. To examine whether such a relationship
exists, for each of the fourteen datasets, the 163 path-
ways were ranked by Student’s t-test p-value. At each
rank, a box plot was prepared to summarize the sizes of
the pathways occupying that rank in the fourteen data-
sets. Then the median pathway sizes are joined to show
the overall trend between size and rank (Additional file
2). Overall, there were no strongly discernible trends
that are suggestive of the size-rank relationship of path-
ways. Another potential problem of the pathway-level
aggregation approach is a possible correlation between
pathways whose member genes partially overlap. For
such pathway pairs, a pathway that is actually irrelevant
to the given phenotype may assume a discriminative














Dana-Farber cohort Michigan cohort
(B) Pathway expression profile of MAPK signaling pathway
Grade 1 Grade 3 Grade 1 Grade 3
Figure 8 Expression profiles of MAPK signalling pathway as an example of discordant pathway. Expression profiles of MAPK signalling
pathway in the two cohort datasets of lung cancer grade are shown. (A) Expression profile of 244 member genes. (B) Pathway expression
profiles aggregated by the six methods. In grade 3, the pathway shows an up-regulation in the Dana-Farber cohort but a down-regulation in
the Michigan cohort.
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expression profile merely because it shares many mem-
ber genes with the other relevant and genuinely discri-
minative pathway. It is desirable to avoid identifying
such an irrelevant pathway as discriminative since it
would otherwise confound the interpretation of the
results. In the domain of functional enrichment analysis,
this problem has been addressed by approaches such as
performing separate analyses on the shared and unique
member subsets in the pathways [36], and giving smaller
weights to the genes that assume intermediate positions in
the pathway network topology, which are likely to be
shared among pathways [37]. Similar lines of approach may
be possible in the domain of pathway-level aggregation.
There are four major strengths in the evaluation
scheme adopted in this study, which raise validity of the
reported results. First, the evaluation is comprehensive
due to the use of seven pairs of related but independent
datasets. Evaluating the performance under a multitude
of datasets encompassing various phenotypes helps to
draw a generalized conclusion. As shown in Figure 6,
both the median and the distribution of accuracies varied
across the seven phenotypes. If only the datasets from a
couple of phenotypes had been used for benchmarking
(for example, Figures 6D and 6F), it would have been
incorrectly concluded that the six compared methods did
not differ in their median accuracy. Second, the evalua-
tion is stringent by externally validating classification
accuracy on independent datasets. Third, the evaluation
is transparent since the classification accuracy was exam-
ined as a function of feature set size (from top one to ten
pathways, ranked by t-test on pathway-level aggregated
data), instead of at a fixed arbitrary number of features,
or an optimized number of features that results in the
best performance in the validation dataset [8]. While the
resultant fluctuations in accuracy across the feature set
sizes (Figure 3) may make the performance comparison
less evident, they transparently show that the expression
profile of top-ranked differentially regulated pathways
might be discordant between datasets. Fourth, the evalua-
tion was also done with respect to the reproducibility of
pathway signatures by examining correlation of pathway
t-statistics between datasets. Its results further substanti-
ate the discordance of pathway signatures between data-
sets, especially under Mean CORGs and PLS-based
aggregation.
There are also three minor contributions in this study.
First, the collection of seven pairs of related but indepen-
dent gene expression datasets can be used for benchmark-
ing analysis of any methods based on gene expression
data. Second, the sign ambiguity of PCs in PCA has been
explicitly stated and resolved. Some of the previous studies
that used PCA as an aggregation method either over-
looked the sign ambiguity issue [6,7], or simply pointed
out that the PCA-aggregated expression profile is not
readily interpretable since it does not capture the direction
of expression changes of pathways [4]. The present study
explicitly stated the issue and followed a simple available
approach that corrects the signs of PC scores so that the
PC scores are positively correlated with the pathway’s
average gene expression profile [15,17]. An alternative
solution [16] has also been proposed in the field of chemo-
metrics, in which the sign of PCs are determined by com-
puting the sign of the sum of inner products between PC
and all data points in the dataset. A preliminary analysis
employing this approach did not result in better classifica-
tion accuracy (data not shown), thus it was not considered
further in the analysis. Third, the present study also expli-
citly stated and resolved the sign correction issue of latent
components in PLS, which has been neither stated nor
resolved in a previous study that used PLS as a pathway-
level aggregation method [4].
In light of the findings obtained from this study, it
appears that there is both room and necessity for develop-
ing a novel method for pathway-level aggregation. On one
hand, considering that averaging the expression profiles of
all pathway member genes (that is, Mean all) results in
the lowest accuracy, it is remarkable that simply removing
half of the genes with lower t-statistics (that is, Mean top
50%) leads to the highest accuracy (Figure 4B). On the
other hand, any method that is dependent on the path-
way’s overall change direction, as in Mean CORGs and
PLS, is likely to manifest the discordance between inde-
pendent datasets. This issue needs to be considered and
resolved in developing a novel method, since one of the
expectations in pathway-level aggregation has been that
the expression of the pathway as a whole may become
more consistent, predictive, and reproducible across inde-
pendent datasets despite gene-level inconsistencies [5,9].
Conclusions
In conclusion, this study evaluated and compared the six
methods for pathway-level aggregation of gene expression
data. Comprehensive and stringent evaluation was made
possible by collecting seven pairs of related but indepen-
dent datasets encompassing various phenotypes. The eva-
luation was performed with respect to classification
accuracy, validated both internally and externally, and by
examining the correlative extent of pathway signatures
between the dataset pairs. The best accuracy and correla-
tion were obtained when pathway-level expression profiles
were derived by ASSESS and Mean top 50%. Thus these
two methods are suggested to be the preferable solutions.
The lowest accuracy was obtained from Mean all. PLS
and Mean CORGs gave rise to the largest extent of discor-
dance in the pathway signature correlation. The analysis
shown in this report also implies that there is both room
and necessity for developing a novel method for pathway-
level aggregation.
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Methods
Collection of benchmarking datasets
The seven pairs of independent datasets were collected by
searching the public repositories and the literature under
the following criteria. First, the search was confined to
human datasets to simplify the data processing and analy-
sis. Second, only the two-class unpaired datasets were con-
sidered for inclusion into the collection. Third, only the
datasets employing relatively recent Affymetrix platforms
were considered, that is, excluding cDNA platforms or
older Affymetrix platforms such as Human Genome U95.
The reason was to ensure a good coverage of genome and
thus a reliable representation of a pathway’s member set.
Fourth, any of the two classes was required to contain ten
or more samples to facilitate internal cross-validation.
Fifth, and most importantly, there should be two related
but independent datasets with identical phenotypic class
labels under investigation (for example, two datasets that
compared lung tissue between smokers and non-smokers),
generated from independent laboratories.
Pre-processing of gene expression data
Data were downloaded from public repositories indicated
in Table 1. The data were obtained as CEL files in all data-
sets, except for the two datasets on lung cancer grade in
which the data are available only as Gene Expression
Omnibus (GEO) series matrix files. The CEL files were
pre-processed by RMA method and log2-transformed. The
GEO series matrix data were already in an RMA-pro-
cessed form (GSE3141) or a GCRMA-processed form
(GSE8894). Expression data from probesets without Entrez
and gene symbol annotations (based on Affymetrix anno-
tation release 30) were discarded. Then expression levels
from multiple probesets representing the same gene were
averaged, yielding gene-level expression profile data con-
taining the following numbers of unique genes: 13,029
genes (U133A and U133A 2.0); 20,315 genes (U133 Plus
2); and 18,485 genes (U133 Set). For three of the seven
phenotypes, a pair of independent experiments was
performed in different platforms. In such cases, the genes
that are commonly represented in both platforms were
selected, which were a subset of one of the platforms with
larger coverage (that is, genes in U133A were a subset of
the genes in U133 Plus 2). Then only the expression data
of the common genes were used for the analysis of the
corresponding phenotype.
Pathway-level aggregation of gene expression data
The gene expression data were aggregated at KEGG
pathway level. The list of KEGG pathways and their
member genes was obtained from MSigDB version 3.0
[38] which contained a total of 186 KEGG pathways.
Among them, there were 163 pathways consisting of at
least 20 and at most 300 member genes, which were used
for subsequent pathway-level aggregation. For the three
mean-based aggregation methods (Mean all, Mean top
50%, and Mean CORGs), an R code was written to imple-
ment them. For ASSESS, its java program was used under
its default parameter setting. For PCA and PLS, modu-
leEigenegenes function in WGCNA package [39] and pls
package [40] were used, respectively. For both PCA and
PLS, the signs of elements in the component score vector
were corrected so that the score vector is positively cor-
related with average gene expression profile of the given
pathway. Prior to aggregation, gene expression data were
z-scaled for all the methods, except for ASSESS which
does not require its input to be z-scaled.
Selection of features used for classification
In each of the fourteen datasets, features (that is, path-
ways) were first ranked by their p-values from Student’s
t-test on the pathway-level expression data. Top pathways
were then selected, whose expression values were used for
subsequent training of classifiers and their performance
evaluation. The number of selected pathways was varied
from one to ten in order to transparently assess the classi-
fier’s performance across a range of features.
Consideration of class imbalance
All the fourteen datasets showed class imbalance–there
were more samples in case group than in control group.
With such datasets, a majority-class classifier is often
obtained since conventional misclassification error rate
can be made meaninglessly low simply by predicting all
samples as a case sample. To correct for the class imbal-
ance problem, three measures were taken–two in classifier
training and one in performance evaluation, as described
in the next two sections.
Parameter tuning of SVM classifier
Classification was performed with SVM implemented in
the e1071 package. Radial basis function was chosen as a
kernel. There are two SVM parameters that affect decision
boundary and thus need to be tuned. They are cost and
gamma whose default values in the e1071 package are 1
and 1/number of selected features, respectively. In the cur-
rent analysis, the parameter tuning was performed by a
grid search in which the cost parameter was varied as C =
2-4, 2-3, ..., 26 and the gamma range was the cost values
divided by the number of selected features. To perform
grid search, 5-fold cross-validation was performed to select
the best pair of the parameter values that minimizes an
error function, which was subsequently used to train clas-
sifiers for validation of classification performance. During
the grid search, two measures were taken in order to
guard against the class imbalance problem. First, class
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weight parameter (class.weights) was set to the inverse of
class proportion, instead of the default equal weights, in
order to compensate for the effect of unbalanced class
proportions. Second, error function parameter (error.fun)
was set to average classification error, which is the mean
of false positive rate and false negative rate, instead of the
default misclassification rate, which is an overall propor-
tion of all the misclassified samples. Since the average clas-
sification error is the mean of the two error rates, a
majority-classifier that classifies most of the samples as
positives would get a high false positive rate and thus a
high average classification error.
Balanced accuracy as the measure of classification
performance
As in the training phase, a measure was taken to guard
against the class imbalance problem by adopting
balanced accuracy as the performance measure. The
balanced accuracy is defined as the mean of true positive
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Figure 9 Illustration of analysis steps. Hyperparameter tuning, internal and external validations, and rank aggregation of the validation results
are depicted.
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would get a low true negative rate and thus a low
balanced accuracy, whereas its conventional accuracy
(overall proportion of correct classifications) can be
meaninglessly high.
Validation of classification performance
Using the balanced accuracy as the performance mea-
sure, a stringent evaluation of classification performance
was performed, which consists of both internal and exter-
nal validations. For the internal validation, 5-fold cross-
validation was performed in a stratified manner such that
class proportions in each training set are kept the same
as in the original dataset. At each iteration of cross-vali-
dation, pathway-level aggregation and feature selection
were performed anew, as has been emphasized as being
the correct practice of cross-validation [41,42]. To
achieve more stable cross-validation results, any possible
effect of a particular random split needs to be avoided.
Thus the cross-validation was repeated twice to obtain a
mean balanced accuracy averaged over five folds and two
repetitions. Only two repetitions were achievable since
the ASSESS program is available as a GUI implementa-
tion instead of a command line version and since a single
iteration of the cross-validation experiment alone
involves a total of seventy training-test set pairs (five
folds times fourteen datasets) each of which need to be
aggregated at pathway-level by the ASSESS and all other
methods. For the external validation, a classifier was
trained on one dataset and tested on the other dataset for
each of the seven pairs of independent datasets.
Summarization of performance rankings across the
datasets
For each of the fourteen datasets, six methods were
ranked according to their balanced accuracy values. The
resultant fourteen ranked lists of six methods were com-
bined into a single ranked list with RankAggreg package
[32]. In brief, accuracies from the six methods were
ranked from the highest to the lowest in each of the
fourteen datasets. At each feature set size, a total of
fourteen ranked lists were thus obtained. Each of the
lists arranges the six methods according to their accura-
cies at the given feature set size and dataset. At each
feature set size, a combined ranking of the methods was
then obtained by merging the fourteen ranked lists with
the RankAggreg package. Using the package, brute force
rank summarization was performed with balanced
accuracies as weights and Spearman footrule distance as
a distance measure. All the aforementioned analysis
steps are depicted in Figure 9.
Softwares
In addition to the aforementioned softwares for pathway-
level aggregation, classification, and rank aggregation, the
analysis performed in this paper used R and Perl for
numerical computation and data parsing. All plots were
generated using ggplot2 R package.
Additional material
Additional File 1: Supplementary Methods. This document contains
the schematic and mathematical description of the pathway-level
aggregation methods.
Additional File 2: Relationship between size and rank of pathways.
The 163 pathways, whose sizes are between 20 and 300, are ranked by
Student’s t-test p-value in all fourteen datasets. Smaller ranks correspond
to more significance. For each rank, a box plot was prepared to
summarize the sizes of the pathways at that rank in the fourteen
datasets. Median sizes are joined by thick line to show the overall size-
rank trend.
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